ESSA Pharma trades as part of the healthcare sector and drug manufacturers industry. The company CEO is David R. Parkinson. ESSA Pharma Inc is a pharmaceutical company. The company is in preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer.



Previous Intraday Performance:

The EPIX shares had a previous change of -0.34% which opened at 2.30 and closed at 2.37. It moved to an intraday high of 2.45 and a low of 2.30.

PR Newswire:  ESSA Pharma Announces Abstract Presentation at the 2019 American Urological Association Annual Meeting

Historical Performance:

Over the last five trading days, EPIX shares returned 11.62% and in the past 30 trading days it returned -36.41%. Over three months, it changed -40.70%. In one year it has changed -25.88% and within that year its 52-week high was 5.83 and its 52-week low was 1.87. EPIX stock is 26.84% above its 52 Week Low.

Our calculations result in a 200 day moving average of 3.26 and a 50 day moving average of 3.40. Right now, EPIX stock is trading -27.18% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

PR Newswire:  ESSA Pharma Announces Abstract Presentation at the 2019 American Urological Association Annual Meeting

Liquidity:

The company has a market cap of $13.7m with 5.8m shares outstanding and a float of 5.8m shares. Trading volume was 2,899 shares and has experienced an average volume of 11,066 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for ESSA Pharma was -2.63 which ended on 30th of September 2018.

The next earnings report will be: 05-09-2019

The long-term trend of the EPS is an important number as it indicates the present value of ESSA Pharma.

Indicators Also to Watch:

Based on the latest filings, there is 87.10% of institutional ownership.



I calculated the beta to be 2.03

SeekingAlpha:  Celestica Inc. 2018 Q4 – Results – Earnings Call Slides

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -5,324.59%, return on assets is -147.17% and price-to-book is 2.23.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here